Penny Stock Rallies on EpiPen Rival

Adamis Pharma's Symjepi will directly compete with Mylan's popular EpiPen

Digital Content Manager
Jan 17, 2019 at 9:59 AM
facebook X logo linkedin


The shares of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) have added 11.2% to trade at $2.92 in early market trading, on the U.S. launch of the company's allergy treatment, Symjepi. The drug -- launched by commercial partner Sandoz -- will directly compete with pharma company Mylan's (MYL) popular EpiPen. The jump has ADMP stock pacing for its third straight win today, and on track for its best session since late September.

The pharma concern has been on the rebound since it bottomed out at a 10-year low of $2.01 on Dec. 20. The shares have rallied roughly 45% since then, and are set to topple their 120-day moving average today -- a trendline it hasn't conquered since September. 

Analysts have remained quietly optimistic on the stock. Of the three who do follow ADMP, two give it a "buy" or better rating, and one issued a "hold." The lofty consensus 12-month price target of $7.00 represents a 140.5% premium to current levels. 

Short interest dropped 8.3% in the most recent reporting period. However, the 3.6 million shares still sold short still represent a healthy 11.5% of the stock's available float. At ADMP's average trading volume, it would take over a week for traders to cover these pessimistic positions.

Prior to today, options traders could scoop up ADMP's near-term contracts at a relative bargain. The equity's Schaeffer's Volatility Index (SVI) of 94% is higher than only 10% of all other readings from the past year. This means that near-term options are pricing in relatively low volatility expectations. 

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI